NASDAQKZIA

Tonpor Kasa Kazia Therapeutics (NASDAQ:KZIA) stock soared 142% in morning trading Wednesday after the company reported positive Phase 2/3 results for its drug paxalisib in the treatment of glioblastoma. A primary analysis of the study, called GBM-AGILE, showed a median overall survival of 14.77 months for paxalisib treated patients versusContinue Reading